HEART failure with preserved ejection fraction (HFpEF) is present in 74% of patients with severe isolated secondary tricuspid ...

An ejection fraction >35% is unconventional to be considered "preserved," so the results of this trial are inconclusive on whether patients with heart failure and ejection fractions usually ...

Implantation of the Ventura interatrial shunt, while safe, does not improve clinical outcomes or prognosis in patients with HF and preserved LVEF.

Understanding how patients with heart failure with preserved ejection fraction (HFPEF) die provides insight into the natural history and pathophysiology of this complex syndrome, thereby allowing ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

led to an 18% reduction in cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ. Ejection fraction is a measure of how much ...

Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart ...

Systolic heart failure happens when the heart pumps at 40% or less of its ejection fraction. Ejection fraction measures how much blood the heart pumps with each contraction or beat. Systolic heart ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...